GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Another potential DIC/sepsis competitor is Tifacogin, which NVS picked up when it acquired Chiron earlier this year.

Tifacogin failed in a phase-3 sepsis trial in 2001, and hence I had assumed that the compound was dead:

http://www.bioportfolio.com/news/biotracker_160.htm

However, NVS might be attempting to resuscitate this compund for sepsis. I’ll pay attention to anything that may be revealed at NVS’ R&D Day on Nov 28.